Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 4 1Phase 2 1

Status

Completed 7Recruiting 4Unknown 3Terminated 3

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 5NET 3

Conditions

Neuroendocrine Tumors 3

Interventions

lutetium Lu 177 dotatate 4lanreotide 3Temozolomide 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3(177)Lu-DOTA-EB-TATE 3anlotinib 2Positron Emission Tomography Computed Tomography 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Metformin 2Everolimus 2Etoposide 2Cisplatin 2Capecitabine 2Biopsy 2surufatinib 1sintilimab 1regorafenib 1recombinant interferon alpha 2b-like protein 1pembrolizumab 1gallium Ga 68 dotatate 1copper dotatate CU-64 1cabozantinib 1amino-acid, glucose, and electrolyte solution 1Yttrium-90 1Tomography, Emission-Computed, Single-Photon 1Thalidomide 1Tegafur 1Surgical Procedures, Operative 1Somatostatin 1Rose Bengal B 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × lanreotide × NET × Clear all
NCT04427787 2021-09-05

LOLA

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Unknown
69 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT02823691 2021-06-07

MetNET-2

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase EARLY_PHASE1 Unknown
20 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03083210 2019-05-20

Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET

Samsung Medical Center

Phase 4 Unknown
28 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡